A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL
NCT05178836
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
62
Enrollment
INDUSTRY
Sponsor class
Conditions
RR DLBCL; PD-1; CD20
Interventions
DRUG:
F520+F007
Sponsor
Shandong New Time Pharmaceutical Co., LTD